You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
Models for Disease Progression: New Approaches and Uses
|
|---|---|
| Published in |
Clinical Pharmacology & Therapeutics, May 2012
|
| DOI | 10.1038/clpt.2012.53 |
| Pubmed ID | |
| Authors |
D R Mould |
| Abstract |
Disease-progression models are useful tools in drug development. They increase the information obtained from clinical trials, improve study designs, and allow in silico evaluations of new treatment combinations and dose regimens. Disease-progression modeling can save time and strengthen "go/no-go" criteria. The use of meta-based modeling and the linking of disease progression to discrete clinical end points have improved the utility of this valuable approach. This article provides an overview of disease-progression evaluations using these new approaches. |
Mendeley readers
The data shown below were compiled from readership statistics for 101 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 4 | 4% |
| United Kingdom | 2 | 2% |
| Australia | 1 | <1% |
| Spain | 1 | <1% |
| Cuba | 1 | <1% |
| Unknown | 92 | 91% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 28 | 28% |
| Student > Ph. D. Student | 26 | 26% |
| Other | 6 | 6% |
| Student > Bachelor | 5 | 5% |
| Student > Postgraduate | 5 | 5% |
| Other | 14 | 14% |
| Unknown | 17 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 23 | 23% |
| Computer Science | 16 | 16% |
| Pharmacology, Toxicology and Pharmaceutical Science | 10 | 10% |
| Agricultural and Biological Sciences | 9 | 9% |
| Engineering | 6 | 6% |
| Other | 15 | 15% |
| Unknown | 22 | 22% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 August 2012.
All research outputs
#15,248,503
of 22,673,450 outputs
Outputs from Clinical Pharmacology & Therapeutics
#3,352
of 4,176 outputs
Outputs of similar age
#104,381
of 164,353 outputs
Outputs of similar age from Clinical Pharmacology & Therapeutics
#28
of 37 outputs
Altmetric has tracked 22,673,450 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,176 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.0. This one is in the 12th percentile – i.e., 12% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 164,353 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 25th percentile – i.e., 25% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 37 others from the same source and published within six weeks on either side of this one. This one is in the 5th percentile – i.e., 5% of its contemporaries scored the same or lower than it.